Stay updated on Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The record for the surufatinib–tislelizumab trial is displayed with its terminated status, study results, eligibility criteria, locations, and study documents.
    Difference
    69%
    Check dated 2026-11-11T00:49:07.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2.
    Difference
    0.2%
    Check dated 2026-11-03T23:15:01.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    A general NIH notice about the terminology transition appears above the ClinicalTrials.gov 403 error page. The displayed site revision changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T22:40:24.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The footer revision number was updated from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-06T22:56:42.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the study details with an access-denied message and signaling that the study record cannot be viewed at the moment.
    Difference
    20%
    Check dated 2026-09-23T01:08:45.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    The page’s revision identifier was updated from v3.6.6 to v3.7.0, signaling a newer edition of the page content. This update is a metadata change that does not modify the study details.
    Difference
    0.0%
    Check dated 2026-09-15T23:53:31.000Z thumbnail image

Stay in the know with updates to Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.